Latest Announcements

Investor Announcement, Huntington's Disease

EMA publishes minutes recommending Orphan Drug Designation for PBT2

Prana Biotechnology Limited today announced that the European Medicines Agency (EMA) has published the Minutes from the April 2015 Meeting of its Committee for Orphan Medicinal Products (COMP), detailing the recommendation from the COMP that PBT2 be granted Orphan Designation in Europe. Prana announced the positive COMP recommendation on 28 April, 2015.


Investor Announcement, Huntington's Disease

PBT2 recommended for orphan designation in Europe

Prana Biotechnology is pleased to announce the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC).


Movement disorders expert Professor Ira Shoulson joins Prana Biotechnology's Board of Directors

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"